Oral Presentations - Pathology and Laboratory Medicine - University ...

ResidentClinical SciencesArwa Al-Riyami 1 , Kristine Roland 1,2 , Kate Chipperfield 1,21Department of Pathology and Laboratory Medicine, University of British Columbia2Department of Pathology and Laboratory Medicine, Vancouver General HospitalAbstract # 1Arwa Al-Riyamioctaplex usage one year after implementation at atertiary care hospitalBackround/ObjectivesOctaplex® is a Human Prothrombin Complex Concentrate that was licensed by Health Canada in 2008 for theemergent management of acquired prothrombin complex deficiency (ie warfarin therapy). The product has been in useat our tertiary care hospital since September 2008. Requests for Octaplex® require Hematopathologist approval, andthe dose is dependent on patient’s weight and INR. Recent national recommendations for dosing Octaplex® conflictsomewhat with the manufacturer’s approach, resulting in Hematopathologist discretion when deciding on a dose.This review evaluated our institution’s experience with Octaplex® use in emergency settings. We wished to examineconsistency of dosing regimens and the efficacy of doses administered.MethodsWe performed a retrospective review of all issues of Octaplex® from Vancouver General Hospital’s blood bank fromSeptember 1st 2008 to January 31st 2010. Clinical indications and details of product administration were obtained bymanual review of patient medical records. Data obtained included clinical indication and the doses administered. Preand post treatment INR’s and patient outcomes were documented.ResultsA total of 42 orders for Octaplex® were received between September 2008 and January 2010 inclusive. Most ofthe orders received were from the Emergency department (18 patients), with the most common indication being alife threatening bleed (69%) . The most frequently administered dose was 1000 IU (range 500-4000). Treatmentsuccess rates at reducing the INR to